Overview

Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas

Status:
Completed

Trial end date:
2004-06-01

Target enrollment:

Participant gender:

Summary

Demonstrate efficacy of telithromycin over single-agent oral antibiotics usually prescribed by local guidelines ("usual care") for treating adult outpatients with mild to moderate community-acquired pneumonia (CAP) in high bacterial resistance areas.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Telithromycin